Introduction {#sec1-1759091417719201}
============

Cerebrovascular dysfunction is resurfacing as a critical pathological component of the onset and progression of cognitive decline in Alzheimer's disease (AD; [@bibr57-1759091417719201]). Indeed, vascular risk factors that are linked to cerebrovascular dysfunction increase AD risk and progression ([@bibr28-1759091417719201]; [@bibr39-1759091417719201]; [@bibr38-1759091417719201]; [@bibr22-1759091417719201]; [@bibr99-1759091417719201]; [@bibr80-1759091417719201]; [@bibr90-1759091417719201]). Further, increased cerebrovascular leakiness, reduced cerebral blood flow, and altered cerebrovascular coverage have all been demonstrated both in AD patients and mouse models of AD-like pathology ([@bibr89-1759091417719201]; [@bibr23-1759091417719201]; [@bibr68-1759091417719201]). Known AD risk factors and processes (which we collectively term AD hits) may contribute to AD by disrupting the cerebrovasculature ([@bibr84-1759091417719201]). As the homeostatic interface between the blood and the brain, the cerebrovasculature is susceptible to damage from AD hit-modulated processes from both the brain and periphery. Therefore, dissecting the impact of AD hits on cerebrovascular dysfunction in AD is crucial.

Amyloid-β (Aβ), *apolipoprotein E4* (*APOE4*), and peripheral inflammation are key AD hits that are independently linked to AD progression and cerebrovascular dysfunction. High soluble and extracellular Aβ levels are important features of AD. Furthermore, Aβ disrupts brain endothelial cells *in vitro* ([@bibr49-1759091417719201]) and mouse models that overproduce Aβ via familial AD mutations are associated with cerebrovascular dysfunction ([@bibr32-1759091417719201]). *APOE4* is the strongest genetic risk factor for AD and carries a 12-fold increase in risk compared to *APOE3* ([@bibr17-1759091417719201]; [@bibr29-1759091417719201]; [@bibr5-1759091417719201]; [@bibr31-1759091417719201]; [@bibr52-1759091417719201]). *APOE4* is also associated with increased cerebrovascular leakiness and lower capillary coverage in both aging and AD (reviewed in [@bibr84-1759091417719201]). Chronic peripheral inflammation is a common feature of nongenetic peripheral AD risk factors. Type 2 diabetes, midlife hypercholesterolemia, midlife hypertension, and atherosclerosis all have a peripheral inflammatory component ([@bibr76-1759091417719201]; [@bibr25-1759091417719201]; [@bibr35-1759091417719201]; [@bibr75-1759091417719201]). Acute peripheral inflammation also induces cerebrovascular damage *in vivo*, and cytokines disrupt brain endothelial cells *in vitro* ([@bibr3-1759091417719201]; [@bibr73-1759091417719201]; [@bibr56-1759091417719201]; [@bibr26-1759091417719201]; [@bibr71-1759091417719201]). While Aβ, *APOE4*, and peripheral inflammation are independently associated with cerebrovascular dysfunction, increasing evidence for other AD-like pathology supports that they interact. For example, *APOE4* and peripheral risk factors interact to increase AD risk ([@bibr33-1759091417719201]; [@bibr40-1759091417719201]; [@bibr60-1759091417719201]), *APOE4* is associated with higher Aβ levels, and peripheral inflammation induces more severe hyperthermia with *APOE4* in humans ([@bibr30-1759091417719201]). The goal of this study was to determine whether *in vivo*, *APOE4* and Aβ predispose the cerebrovasculature to damage in response to chronic repeated peripheral inflammation.

EFAD mice ([@bibr96-1759091417719201]; [@bibr85-1759091417719201]) are a well-characterized mouse model that express human *APOE3* (E3FAD) or *APOE4* (E4FAD) and overproduce human Aβ42 (EFAD+), whereas littermate controls express *APOE3* or *APOE4* in the absence of human Aβ (EFAD−). Thus, EFAD mice are well-suited to determine the *APOE*-modulated contribution of AD relevant hits in the presence or absence of human Aβ. We therefore utilized EFAD mice in this study. Chronic repeated peripheral challenge with lipopolysaccharide (LPS; 0.5 mg/kg/wk, from 4 to 6 months of age) induced cognitive and cerebrovascular deficits in E4FAD+ mice. These data support that cerebrovascular dysfunction is a key mechanism that links AD hits to pathogenesis.

Materials and Methods {#sec2-1759091417719201}
=====================

Animals {#sec3-1759091417719201}
-------

Breeding and colony maintenance was conducted at the University of Illinois at Chicago as previously described ([@bibr96-1759091417719201]; [@bibr86-1759091417719201]), and all protocols adhere to the University of Illinois at Chicago Institutional Animal Care and Use Committee protocols.

EFAD mice express human *APOE3* or *APOE4* and overproduce human Aβ via the expression of five Familial Alzheimer's disease (5xFAD) mutations ([@bibr96-1759091417719201]). EFAD mice were generated by crossing *APOE*-targeted replacement (*APOE*-TR) mice on a C57/BL6 background with female 5xFAD mice on a C57BL6/B6xSJL background. The resulting male offspring were then backcrossed to female *APOE*-TR mice to produce 5xFAD^+/−^/*APOE*^+/+^ (EFAD) mice. EFAD mice are maintained as an inbred strain, by crossing male EFAD+ with female EFAD− mice, or vice versa. Therefore, the offspring produced express human apoE as either carriers or noncarriers of the 5xFAD mutations ([@bibr96-1759091417719201]).

Male EFAD carrier \[5xFAD^+/−^/*APOE*^+/+^ (EFAD+)\] and noncarrier \[5xFAD^−/−^/*APOE*^+/+^ (EFAD−)\] mice utilized in this study were grouped into 10 cohorts (*n* ≥ 8 per cohort), and treatments were randomized by cage. Female mice were excluded from this study as female sex is in itself a risk factor for AD. We have previously demonstrated cognitive and cerebrovascular deficits in female E4FAD+ mice ([@bibr86-1759091417719201]). Therefore, the focus here was whether peripheral inflammation induces similar cerebrovascular and cognitive dysfunction in male E4FAD+ mice. EFAD mice used to begin the breeding colonies were a generous gift of Dr. M. J. LaDu. All investigators were blinded for LPS treatment.

LPS Treatment {#sec4-1759091417719201}
-------------

EFAD mice were administered phosphate-buffered saline (PBS) or LPS (*Escherichia coli* O8:K27 \[S-form\], Innaxon) via intraperitoneal (i.p.) injection (0.5 mg/kg/wk) from 4 to 6 months of age. A final LPS treatment was administered the day before sacrifice for nine total injections ([Figure 1(a)](#fig1-1759091417719201){ref-type="fig"}). Body weights were measured prior to each injection. Figure 1.(a) Study design. (b) Body weight is unaffected by LPS treatment. Body weight was tracked weekly over the course of LPS treatment from 4 to 6 months of age. No differences were detected between genotypes or treatment groups. *p* \> .05 using a mixed effects model.

Behavioral Analysis {#sec5-1759091417719201}
-------------------

Behavioral tests to assess cognitive function were initiated 2 days after the eighth regular treatment injection of LPS or PBS and concluded 2 days prior to the final injection ([Figure 1(a)](#fig1-1759091417719201){ref-type="fig"}). Mice were sequentially assessed (24 hr between tests) by spontaneous alternation (Y-maze) and novel object recognition tests as described in [@bibr86-1759091417719201] with slight modification. All behavioral analysis was conducted during the mouse dark cycle, recorded by an overhead camera, and analyzed using ANY-Maze software. A potential caveat is that sequential behavioral tests modifies performance (i.e., any differences observed in novel object recognition are related to LPS-driven performance deficits over 3 days of testing). We have attempted to minimize such an effect by staggering the tests from least to most complex or stressful (i.e., spontaneous alternation then novel object recognition with a 24 hr gap in-between) to minimize multitesting effects.

Spontaneous Alternation (Y-maze) {#sec6-1759091417719201}
--------------------------------

Mice were placed in the entry arm of a Y-maze apparatus (38.5 × 8 × 13 cm, spaced 120° apart) and allowed to explore freely for 10 min. The sequence of arm entries was recorded and spontaneous alternation calculated: number of alternations (three successive entries that include one instance in each arm) divided by the total possible alternations (number of arms entered minus 2) multiplied by 100.

Novel Object Recognition {#sec7-1759091417719201}
------------------------

Briefly, mice were habituated in a white testing arena (33 × 25 × 12.5 cm) for 10 min, allowed to rest in their home cage for 50 min, and then returned to the same testing arena for 10 min. After 24 hr, mice were placed in the same testing arena with two identical objects for 10 min. After being returned to their home cage for 50 min, they were placed back into the testing arena containing a familiar and novel object for 10 min. The discrimination index (DI) was calculated as: $\text{DI} = \frac{(\text{T}_{\text{N}} - \text{T}_{\text{F}})}{(\text{T}_{\text{N}} + \text{T}_{\text{F}})}$, where T~N~ is the time spent exploring the novel object and T~F~ is the time spent exploring the familiar object.

Tissue Harvest {#sec8-1759091417719201}
--------------

Twenty-four hours after the final injection of LPS, EFAD mice were injected i.p. with 200 µl of 2% sodium fluorescein (NaFl, see below for quantification) in sterile ddH~2~O and anesthetized 30 min later with ketamine (100 mg/kg) and xylazine (10 mg/kg). Following anesthetization, blood was drawn from the right ventricle of the heart using a heparin-coated needle and centrifuged at 1,500 × *g* for 15 min at 4℃ to collect the plasma. The plasma was analyzed immediately for NaFl extravasation or snap frozen in liquid nitrogen and stored at −80℃.

Mice were then transcardially perfused with PBS containing protease inhibitors (Millipore, Darmstadt, Germany) at a rate of 4 ml/min for 5 min. Dissected left hemi-brains were frozen in Optimal Cutting Temperature (OCT) and stored at −80℃ until immunohistochemical (IHC) analysis. Right hemi-brains were further dissected into the cortex, hippocampus, and cerebellum, weighed, homogenized in PBS, and processed immediately for NaFl extravasation. A fraction of each PBS brain region homogenate was reserved for biochemical analysis.

NaFl Extravasation Analysis {#sec9-1759091417719201}
---------------------------

PBS homogenates were resuspended in equal volumes of 60% tricholoroacetic acid, vortexed, and centrifuged at 18,000 × *g* for 10 min at 4℃. The supernatant was collected and fluorescence was read using a SpectraMax i3x microplate reader (Molecular Devices). Cleared volume of NaFl that passed from the plasma into the brain was calculated as follows: $$\begin{array}{r}
{\text{ClearedVolume} = \frac{\frac{\text{BrainFluorescence}(\text{AU}))}{\text{PlasmaFluorescence}(\text{AU}/\mu\text{l})}}{\text{BrainWeight}(\text{mg})}} \\
\end{array}$$

Biochemical Analysis {#sec10-1759091417719201}
--------------------

Reserved aliquots of PBS extracts from homogenized brain tissue (see NaFl analysis protocol) were further processed using a modified version of the three-step extraction protocol described in [@bibr96-1759091417719201] in order to separate soluble, detergent-soluble, and extracellular proteins. This protocol was developed to assess soluble Aβ levels (considered particularly AD-relevant) and to fully extract total Aβ (which is primarily driven by formic acid levels). In addition, the collection of a detergent soluble fraction enables subsequent analysis of neuronal proteins by Western blot analysis. Briefly, the PBS extracts were centrifuged (100,000 × *g* for 1 hr at 4℃), and the PBS-soluble supernatant was collected, snap frozen in liquid nitrogen, and stored at −80℃ until use. The pellet was washed in Tris-buffered saline (TBS) and resuspended in TBS with 1% Triton X-100 (TBS-X), incubated at 4℃ for 30 min with gentle rotation, and centrifuged (100,000 × *g* for 1 hr at 4℃). The TBS-X-soluble fraction was collected and frozen as described for the PBS extract. The remaining pellet was washed with TBS-X and resuspended in 70% formic acid (FA), incubated with gentle rotation at room temperature for 2 hr with occasional vortexing, and centrifuged (100,000 × *g* for 1 hr at 4℃). The FA-soluble supernatant was neutralized with 20 volumes of 1 M Tris base, aliquoted, and snap frozen in liquid nitrogen. Total protein in the PBS and TBS-X extracts was quantified using the Pierce™ BCA Protein Assay Kit (Thermo Fisher). The ready-to-use Bradford reagent (Bio-Rad) was used to quantify total protein in the neutralized FA extract.

Western Blotting {#sec11-1759091417719201}
----------------

Samples were loaded onto gels to allow comparison of LPS-treated groups against their appropriate PBS vehicle controls (e.g., E4FAD + LPS vs. E4FAD + PBS) with an *n* ≥ 6 of each group per gel. All samples were normalized to actin. Given the larger volume of cortical samples, we were able to run all of the PBS-treated vehicle controls together on four separate gels (*n* = 6 per group), in order to compare protein levels as a ratio of the E3FAD− PBS group. The limited volume of the hippocampal samples prevented us from running samples on the multiple gels required to plot the data as a ratio of the E3FAD− PBS group, as was conducted for cortex samples (i.e., there were only sufficient sample volumes to run a gel comparing PBS- to LPS-treated mice within a genotype, e.g., E4FAD− mice, but not to run separate gel(s) with all the PBS samples across genotypes, i.e., comparing samples from E3FAD−, E3FAD+, E4FAD−, E4FAD+ mice). TBS-X fractions from the three-step extraction were analyzed for neuronal proteins and actin by western blot as described previously ([@bibr86-1759091417719201]). Briefly, protein (15 µg for cortex, 10 µg for hippocampus) was separated on 4% to 12% Bis-Tris gels (Invitrogen), transferred onto low-fluorescence PVDF, blocked with 5% milk in 0.1% Tween-20 in TBS (TBS-T), and probed with primary antibody in 5% bovine serum albumin (BSA): overnight at 4℃ for postsynaptic density-95 (PSD-95, 1:1000, Cell Signaling) and synaptophysin (1:1000, Cell Signaling); 1 hr at room temperature for actin (1:20000, Cell Signaling). After washing (3 × 5 min, TBS-T), membranes were incubated for 1 hr in the appropriate secondary antibody (Jackson Immunoresearch). Proteins were imaged and quantified using the Odyssey ® Fc Imaging System and normalized to actin. Actin-normalized LPS-treated groups are expressed as either a ratio of the E3FAD− PBS-treated group (cortex) or as a ratio of their own PBS-treated vehicle controls (hippocampus).

Enzyme-Linked Immunosorbent Assay {#sec12-1759091417719201}
---------------------------------

ApoE and Aβ42 were measured by enzyme-linked immunosorbent assay (ELISA) in the PBS, TBS-X, and FA extracts. The apoE ELISA was performed as described in [@bibr83-1759091417719201] using anti-apoE (1:2000, Millipore) and biotinylated anti-apoE (1:5000, Meridian) for capture and detection antibodies, respectively. Aβ42 was measured by a commercially available ELISA kit following the manufacturer instructions (Life Technologies).

Fluorescent IHC {#sec13-1759091417719201}
---------------

Laminin and Aβ IHC analysis was conducted as previously described in [@bibr86-1759091417719201]. Succinctly, sagittal sections were taken beginning at the stereotaxic coordinate of ML 3.72 mm through 0 mm in order to encompass the cortex and the entire hippocampal formation. Nine nonadjacent, 12 µm frozen sections (192 µm apart) per animal were fixed with 10% neutral buffered formalin (Sigma). Incubation in FA is a frequently utilized method for antigen retrieval of Aβ and, therefore, was performed here ([@bibr47-1759091417719201]; [@bibr18-1759091417719201]; [@bibr16-1759091417719201]; [@bibr96-1759091417719201]; [@bibr97-1759091417719201]; [@bibr86-1759091417719201]). Following antigen retrieval (52.8% FA, 8 min, room temperature), sections were permeabilized with 0.25% Triton X-100 in TBS (dilution media), blocked in 5% BSA in dilution media, and incubated in primary antibody overnight at 4℃ in a humidified chamber. Anti-Aβ (MOAΒ-2, mouse IgG~2b~, 1:250, Biosensis) and anti-laminin (rabbit, 1:200, Abcam) primary antibodies were diluted in 2% BSA and 0.1% Triton X-100 in TBS. Next, sections were washed 3 × 5 min in dilution media and incubated in the appropriate Alexa fluorophore-conjugated secondary antibodies (1:200, AlexaFluor 350 anti-mouse IgG~2b~, AlexaFluor 750 anti-rabbit, Invitrogen) in 2% BSA and 0.1% Triton X-100 in TBS, followed by 3 × 5 min washes in dilution media, and 1 × 5 min in TBS. Mosaic^[1](#fn1-1759091417719201){ref-type="fn"}^ and single images were obtained at 20 × magnification on a Zeiss Axio Imager M1 under identical exposure settings and equally thresholded on ImageJ software (NIH, ImageJ). Laminin and Aβ levels were quantified in the full cortex, deep layer cortex, and subiculum using the "Analyze Particles" feature. Brain regions of interest were standardized with reference to the Allen Mouse Brain Atlas. Specifically (see Supplementary Figure 1(a)), the cortex included all six layers of the isocortex, whereas the deep layer cortex included only layers 2/3 through 6a of the isocortex. The subiculum was traced for each section excluding other regions of the retrohippocampal region (i.e., the entorhinal area, the parasubiculum, the postsubiculum, and the presubiculum).

Cerebral amyloid angiopathy (CAA)-like deposition was quantified as described in ([@bibr85-1759091417719201]). Briefly, mosaic images costained for Aβ (MOAΒ-2) and laminin were captured using identical settings at 20 × magnification as described for vessel coverage. Converted images were thresholded equally and quantified using the "Colocalization Threshold" feature in NIH ImageJ software.

Tissue sections for confocal microscopy and 3D vessel reconstruction were sectioned as described earlier. Tissue was probed with anti-Aβ (MOAΒ-2, mouse IgG~2b~, 1:250, Biosensis) and anti-laminin (rabbit, 1:200, Abcam) or anti-CD31 (rat, 1:10, BD Bioscience) followed by the appropriate secondary (1:200, AlexaFluor 350 anti-mouse IgG~2b~, AlexaFluor 555 anti-rabbit, AlexaFluor 594 anti-rat, Invitrogen). Representative Z-stack images of cortical vessels with overlapping fluorescence for Aβ and laminin or CD31 were taken at 63× magnification on a Zeiss LSM 710 Confocal Microscope. Imaris 7.7.2 software was used to produce 3D vessel reconstructions and visualize CAA in the cortical cerebrovasculature.

Multiplex Analysis of Peripheral Cytokines {#sec14-1759091417719201}
------------------------------------------

Plasma cytokine levels were measured using a Bio-Plex Pro™ Mouse Cytokine 23-plex Assay (Bio-Rad) according to the manufacturer protocol. For quantification, standard curves were generated using standards for each cytokine (included in the kit) and analyzed using a five-parameter logistic equation. Sample concentrations were calculated based on parameters obtained using the standard curve. Hierarchical cluster analysis was performed using Cluster 3.0 ([@bibr21-1759091417719201]) and visualized using Java Treeview ([@bibr74-1759091417719201]) software.

Statistical Analysis {#sec15-1759091417719201}
--------------------

Sample sizes were as follows: E3FAD − PBS (*n* = 9), E3FAD − LPS (*n* = 7), E3FAD + PBS (*n* = 7), E3FAD +LPS (*n* = 7), E4FAD − PBS (*n* = 10), E4FAD − LPS (*n* = 11), E4FAD + PBS (*n* = 9), and E4FAD + LPS (*n* = 12). All samples were utilized for analysis unless stated in the results. For IHC analysis *n* = 6 for all groups.

A mixed model was used to analyze changes in bodyweight over time and between treatments. The random intercepts and slopes model included linear time, treatment, and their interaction as fixed effects. Overall effects were analyzed by inverse-variance-weighted three-way analysis of variance (ANOVA), testing initially for mean differences using the omnibus *F* test with a saturated model. Post hoc mean comparisons driven by visual inspection of the results were conducted using the appropriate orthogonal contrasts with Bonferroni's correction. Three-way ANOVA and post hoc analysis were carried out with R version 3.3.0 ([@bibr72-1759091417719201]). Weighted two-way ANOVA with Bonferroni's correction and Student's *t*-test analyses were conducted using GraphPad Prism Version 6. All data are represented as the mean ± standard error (SEM).

Results {#sec16-1759091417719201}
=======

Systemic LPS Administration Induces Cognitive Dysfunction in E4FAD+ Mice {#sec17-1759091417719201}
------------------------------------------------------------------------

The overarching goal of this study was to determine the interactive effects of chronic repeated peripheral inflammation, *APOE*, and Aβ on cerebrovascular and AD-like pathology *in vivo*. Wild-type mice were excluded from this study as mouse apoE is structurally distinct from each of the human apoE isoforms. Human apoE isoforms differ by a single amino acid change at residues 112 and 158 (apoE3^Cys,Arg^, apoE4^Arg,Arg^), whereas mouse apoE is expressed as a single isoform and differs from all human apoE isoforms by approximately one third of its nearly 300 amino acids ([@bibr85-1759091417719201]). The structural differences result in unique functional effects of mouse apoE compared to the human apoE isoforms. Therefore, mouse models were developed to enable a comparison of human *APOE3* to human *APOE4* and to mimic more closely *APOE4*-induced AD risk in humans. To incorporate *APOE* and Aβ, EFAD mice were employed, which express human *APOE3* (E3FAD mice) or *APOE4* (E4FAD mice) and overproduce Aβ42 via the 5xFAD mutations ([@bibr96-1759091417719201]). Male EFAD carrier \[5xFAD^+/−^/*APOE*^+/+^ (EFAD+)\] and noncarrier \[5xFAD^−/−^/*APOE*^+/+^ (EFAD−)\] mice expressing *APOE3* or *APOE4* were utilized in order to dissect the effects of peripheral inflammation in the presence and absence of high levels of human Aβ. For peripheral inflammation, EFAD mice were treated with LPS, a bacterial endotoxin, and toll-like receptor 4 agonist commonly utilized to induce an inflammatory response. We selected a low dose (0.5 mg/kg i.p.) reported to be the threshold of physiological changes ([@bibr91-1759091417719201]) and only treated mice once a week to achieve a repeated low-level peripheral inflammatory response. Thus, male EFAD+ and EFAD− mice were treated from 4 to 6 months of age ([Figure 1(a)](#fig1-1759091417719201){ref-type="fig"}, LPS, 0.5 mg/kg/wk i.p.) to start at an age of initial Aβ deposition and prior to cognitive deficits ([@bibr96-1759091417719201]; [@bibr86-1759091417719201]).

There were no changes in bodyweight after LPS treatment regardless of *APOE* genotype ([Figure 1(b)](#fig1-1759091417719201){ref-type="fig"}, *F*(1, 67) = 1.97, *p* \> .05). Further, we monitored EFAD+ and EFAD− mice continually over the treatment course and there were no overt signs of toxicity, i.e., death rates (none), fur loss, or wounds. Therefore, no characteristics of sickness behavior were observed, which are frequently associated with higher LPS doses and indicates acute, rather than chronic low-level inflammation.

Initially, the effect of LPS on cognition was assessed. As described in the "Materials and Methods" section, statistical analysis was conducted using a three-way ANOVA *F* test, to determine whether there were significant differences between any groups. Subsequent post hoc analysis was based on hypotheses derived from the scientific interpretation of the graphs, which for behavior and PSD-95 (see below) was focused on comparisons for LPS- and PBS-treated mice within each group. A similar approach was conducted for all three-way ANOVA comparisons throughout the study. LPS treatment had no effect on spatial memory as assessed by spontaneous alternation ([Figure 2(a)](#fig2-1759091417719201){ref-type="fig"}, *p* \> .05). However, the novel object recognition test illuminated dysfunction in recognition memory in LPS-treated E4FAD+ mice compared to PBS-treated E4FAD+ mice ([Figure 2(b)](#fig2-1759091417719201){ref-type="fig"}, *F*(7, 64) = 4.7, \**p* \< .05, followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group). Furthermore, no other groups demonstrated a deficit in recognition memory when challenged with LPS- compared to their own PBS-treated vehicle control. Thus, repeated peripheral LPS challenge resulted in a substantial cognitive deficit in E4FAD+ mice. Figure 2.Cognitive dysfunction in LPS-treated E4FAD+ mice. (a) Spatial memory was unaffected by LPS treatment when assessed by spontaneous alternation (Y-maze). (b) LPS-induced recognition memory deficits in LPS-treated E4FAD+ mice compared to PBS-treated E4FAD+ mice. (c) In the cortex, post-synaptic density-95 (PSD-95) protein levels (normalized to actin) were higher in E3FAD+ mice treated with LPS compared to PBS, indicating a potential adaptive response. In the cortex, there was a nonsignificant trend where, compared to PBS, LPS treatment resulted in lower levels of PSD-95 of E4FAD+ mice. In the hippocampus, E4FAD+ mice treated with LPS had lower PSD-95 levels compared to PBS-treated mice. Solid black boxes indicate samples were run on the same gel; bands on the same gel in nonadjacent positions are separated by a dashed line. Data are expressed as the mean ± SEM. \**p* \< .05 by three-way ANOVA followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group. The exception is for PSD-95 levels in the hippocampus for (c) where \**p* \< .05 by *t*-test.

Next, levels of PSD-95 were assessed by western blot analysis. The extraction procedure utilized in this study resulted in higher cortical volumes for western blot analysis. Thus, as described in the "Materials and Methods" section, we were able to plot expression levels (normalized to actin) as a ratio of the PBS-treated E3FAD− group. There were higher levels of PSD-95 in the cortex of LPS- compared to PBS-treated E3FAD+ ([Figure 2(c)](#fig2-1759091417719201){ref-type="fig"}, *F*(7, 62) = 7.6, \**p* \< .05, followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group). These data indicate an adaptive, potentially protective response. Consistent with the behavioral deficits, there was a nonsignificant trend in which, compared to PBS, LPS treatment resulted in lower levels of the postsynaptic protein PSD-95 in the cortex of E4FAD+ mice ([Figure 2(c)](#fig2-1759091417719201){ref-type="fig"}; *p* = .088). Due to volume restrictions in the hippocampal samples, we could only compare the LPS- and PBS-treated groups (Student's *t*-test). LPS treatment resulted in lower PSD-95 levels only in E4FAD+ mice, with ∼25% lower levels compared to PBS-treated E4FAD+ mice. There were no significant differences in the levels of the presynaptic protein synaptophysin for any of the groups (data not shown). Collectively, these data support that LPS treatment from 4 to 6 months of age induces cognitive deficits and lowers PSD-95 levels in E4FAD+ mice.

Higher Cerebrovascular Leakiness and Lower Vessel Coverage in LPS-Challenged E4FAD+ Mice {#sec18-1759091417719201}
----------------------------------------------------------------------------------------

To determine the roles of peripheral inflammation and *APOE* in cerebrovascular integrity, we first measured NaFl levels in the brain following i.p. injection ([Figure 3](#fig3-1759091417719201){ref-type="fig"}). Cortical NaFl levels were significantly higher in LPS-treated, compared to PBS-treated, E4FAD+ mice ([Figure 3(a)](#fig3-1759091417719201){ref-type="fig"}; *F*(7, 55) = 4.2, \**p* \< .05 followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group; insufficient plasma volumes due to imperfect blood draws resulted in the prioritization of samples for later multiplex analysis and exclusion from NaFl analysis: E3FAD− PBS (*n* = 6), E3FAD− LPS (*n* = 6), E3FAD+ PBS (*n* = 7), E3FAD+ LPS (*n* = 6), E4FAD− PBS (*n* = 10), E4FAD− LPS (*n* = 7), E4FAD+ PBS (*n* = 9), and E4FAD+ LPS (*n* = 12)). Indeed, cortical NaFl levels were ∼300% higher in E4FAD+ mice treated with LPS. There were no other differences when comparing PBS- to LPS-treated mice within any other group. In the hippocampus, LPS treatment did not significantly increase NaFl levels compared to the PBS-treated mice in any group ([Figure 3(b)](#fig3-1759091417719201){ref-type="fig"}; *p* = .07). Lack of an effect for LPS in E4FAD+ mice in the hippocampus may be related to the lower signal-to-noise ratio of the hippocampus. Figure 3.Higher cerebrovascular leakiness in LPS-treated E4FAD+ mice. (a) When assessed by sodium fluorescein (NaFl) extravasation, peripheral administration of LPS resulted in 300% higher cortical NaFl levels in E4FAD+ mice compared to PBS. (b) In the hippocampus, no differences were observed between LPS and PBS groups. Data are expressed as the mean ± SEM. \**p* \< .05 by three-way ANOVA followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group.

Total vessel coverage is an indication of a disrupted cerebrovasculature, and at 8 months of age, we have observed lower vessel coverage in the subiculum and deep layer cortex of female E4FAD+ mice compared to age-matched males ([@bibr86-1759091417719201]). The region-specific lowering of vessel coverage is likely driven by the accumulation of Aβ in those regions of EFAD+ mice and increased susceptibility of vessels to damage (see "Discussion" section). Therefore, the effects of LPS on cerebrovascular coverage were assessed using a staining for laminin, a basement membrane protein, in the full cortex, deep layer cortex, and subiculum (see Supplementary Figure 1(a) for a representative image of brain regions used for quantification), to match our previous study in female EFAD mice. Laminin coverage in the deep layer cortex and subiculum qualitatively appeared lower in E4FAD+ mice that had been treated with LPS compared to PBS ([Figure 4(a](#fig4-1759091417719201){ref-type="fig"}, [b](#fig4-1759091417719201){ref-type="fig"})). Quantification revealed that, in E4FAD+ mice treated with LPS compared to PBS, vessel coverage was 25% lower in full and deep layer cortex and ∼35% lower in the subiculum (*F*(7, 40) = 3.30, 9.78, 13.35 for each brain region, respectively, \**p* \< .05, followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group). The only other group that exhibited significantly lower vessel coverage in the subiculum with LPS versus PBS treatment was E4FAD− mice. These data indicate subtle cerebrovascular deficits in E4FAD− mice after repeated peripheral inflammation that may manifest as cognitive decline with longer treatment. Thus, LPS induces cerebrovascular deficits, including lower cerebrovascular coverage, in male E4FAD+ mice. Figure 4.Lower vessel coverage in LPS-treated E4FAD+ mice. (a) Composite mosaic images stitched together from images taken at 20× magnification. (b) 20× representative images of 12 µm brain sections costained for laminin (green, a basement membrane protein) and extracellular Aβ (blue, IHC using antibody MOAB2). Vessel coverage is visually lower in LPS-challenged E4FAD+ mice. (c) When quantified laminin coverage was significantly lower in E4FAD+ mice treated with LPS in both the deep layer of the cortex and the subiculum compared to PBS treatment. In addition, in the subiculum of E4FAD− mice, there is lower vessel coverage in LPS- compared to PBS-treated mice. Data are expressed as the mean ± SEM. \**p* \< .05 by three-way ANOVA followed by Bonferroni post hoc analysis comparing PBS- with LPS-treated mice within each group.

Higher Extracellular Aβ in the Cortex of LPS-Treated E4FAD+ Mice {#sec19-1759091417719201}
----------------------------------------------------------------

EFAD+ mice serve as a model of *APOE*-modulated Aβ levels and induced dysfunction, with Aβ pathology primarily in the subiculum of the hippocampal formation and in the deep layers of the frontal cortex. Therefore, we assessed whether repeated peripheral challenge with LPS had an effect on brain Aβ42 levels biochemically and by IHC ([Figure 5(a)](#fig5-1759091417719201){ref-type="fig"} to ([c](#fig5-1759091417719201){ref-type="fig"})). As EFAD− mice were not assessed for Aβ, statistical analysis was conducted by two-way ANOVA followed by Bonferroni post hoc analysis. In the cortex, there were no changes in soluble or total Aβ42 levels when assessed biochemically ([Figure 5(a)](#fig5-1759091417719201){ref-type="fig"}, *F*(1, 33), *p* \> .05, see Supplementary Figure 1(b) for full extraction profile). Since total Aβ consists primarily of extracellular Aβ, quantitative IHC analysis was conducted. There was a genotype effect (*F*(1, 20) =21.2, *\*p* \< .05), and post hoc analysis revealed higher levels of Aβ in the cortex of LPS-treated E4FAD+ mice compared to LPS- and PBS-treated E3FAD+ ([Figure 5(c)](#fig5-1759091417719201){ref-type="fig"}, Bonferroni post hoc comparisons comparing all groups). We are careful not to over interpret, due to the difficulty in distinguishing plaque size and number, but the higher percentage area covered by extracellular Aβ in the cortex of LPS-treated E4FAD+ mice was primarily driven by large size (Supplementary Figure 1(d), (*F*(1, 20) = 17.8 for genotype and treatment interaction, *\*p* \< .05, Bonferroni post hoc comparisons comparing all groups). As there were no differences by *APOE* genotype in the PBS group by IHC, these data indicate that LPS increased insoluble Aβ levels in the cortex of E4FAD+ mice. The partial differences between the IHC and biochemical data may be related to the relatively high variation of Aβ levels in the E4FAD+ PBS group; however, visually, the graphs followed the same trend. In the hippocampus, there was both a genotype (*F*(1, 33) = 16.64, *\*p* \< .05) and a treatment interaction (*F*(1, 33) = 8.190, *\*p* \< .05), with higher levels of soluble Aβ (PBS extraction) in the hippocampus of LPS-treated E4FAD+ mice compared to all other groups ([Figure 5(b)](#fig5-1759091417719201){ref-type="fig"}, Bonferroni post hoc comparisons comparing all groups, see Supplementary Figure 1(c) for full extraction profile). Although no differences were observed for total Aβ42, extracellular Aβ primarily deposits in the subiculum of EFAD+ mice, which may have partially confounded biochemical analysis of the entire hippocampus. We therefore quantified extracellular Aβ in the subiculum by IHC. Similar to the cortex, there was a genotype effect in the subiculum (*F*(1, 20) = 13.06, *\*p* \< .05)) with higher levels of Aβ for LPS-treated E4FAD+ mice compared to E3FAD+ mice treated with LPS ([Figure 5(c)](#fig5-1759091417719201){ref-type="fig"}, Bonferroni post hoc comparisons comparing all groups). However, there were no differences for any treatments or genotypes in extracellular Aβ deposit size or count (Supplementary Figure 1(e)). Figure 5.LPS increases Aβ42 levels in E4FAD+ mice. (a) In the cortex, there were no changes in soluble (left panel) or total Aβ42 levels (center panel) when assessed biochemically. Total Aβ is the sum of the amount of Aβ in every fraction divided by the protein content in every fraction. As total Aβ primarily consists of extracellular Aβ, quantitative IHC analysis was conducted (right panel and images). There were higher levels of Aβ in the cortex of LPS-treated E4FAD+ mice compared to LPS- and PBS-treated E3FAD+ mice. (b) In the hippocampus, there were higher levels of soluble Aβ (PBS extraction) in the hippocampus of LPS-treated E4FAD+ mice compared to all other groups. Although no differences were observed for total Aβ42, when extracellular Aβ in the subiculum was quantified by IHC, there were higher levels in LPS-treated E4FAD+ mice compared to E3FAD+ mice treated with LPS. (c) For apoE, the only significant differences were in the soluble (PBS) extracts with lower apoE levels in E4FAD− mice treated with PBS compared to E3FAD− mice treated with PBS. However, there were no effects of LPS treatment on apoE levels compared to PBS controls for any groups. Data are expressed as the mean ± SEM. (a, b) \**p* \< .05 by two-way ANOVA followed by Bonferroni post hoc analysis (c, d) \**p* \< .05 by three-way ANOVA followed by Bonferroni post hoc analysis comparing all groups.

ApoE was also measured by ELISA in both the cortex and the hippocampus to determine if LPS modulated apoE levels.^[2](#fn2-1759091417719201){ref-type="fn"}^ When each fraction was assessed separately, significance in the *F* test was only reached for the soluble (PBS) fraction in the cortex (*F*(7, 58) = 5.0, \**p* \< .05) and the hippocampus (*F*(7, 54) = 5.5, \**p* \< .05). To dissect the changes, we conducted post hoc analysis comparing the different genotypes within the PBS or LPS treatments and PBS versus LPS treatments within groups (with simultaneous analysis using Bonferroni correction). Post hoc analysis demonstrated that there are lower apoE levels in E4FAD− mice treated with PBS compared to E3FAD− mice treated with PBS. However, there were no effects of LPS treatment on apoE levels compared to PBS controls for any of the groups.

Therefore, LPS induced mixed effects on Aβ levels for E4FAD+ mice: higher soluble Aβ levels in the hippocampus biochemically, and, by IHC, higher extracellular Aβ in the cortex and subiculum.

Higher CAA-Like Aβ Deposition in E4FAD+ Mice {#sec20-1759091417719201}
--------------------------------------------

Given that extracellular Aβ42 levels appeared higher in LPS-challenged E4FAD+ mice and the fact that Aβ can deposit in the vasculature, CAA-like deposition was assessed (laminin-Aβ costain). Despite the abundance of Aβ plaques in the subiculum, CAA-like deposition was only evident in the cortex ([Figure 6(a)](#fig6-1759091417719201){ref-type="fig"}). CAA was higher in LPS-treated E4FAD+ mice compared to PBS- and LPS-treated E3FAD+ mice ([Figure 6(b)](#fig6-1759091417719201){ref-type="fig"}, two-way ANOVA, *F*(1, 20) = 23.91, *\*p* \< .05, followed by Bonferroni post hoc comparisons comparing all groups). These data support that CAA is highest in LPS-treated E4FAD+ mice. Next, we assessed the localization of deposited Aβ using confocal microscopy followed by 3D reconstruction of the basement membrane (laminin), vessels (CD31), and Aβ ([Figure 6(c)](#fig6-1759091417719201){ref-type="fig"} to ([e](#fig6-1759091417719201){ref-type="fig"})). In E4FAD+ LPS-treated mice, Aβ was localized within the laminin basement membrane in both larger vessels ([Figure 6(c)](#fig6-1759091417719201){ref-type="fig"}) and capillary-like vessels ([Figure 6(d)](#fig6-1759091417719201){ref-type="fig"}). Costaining of CD31-labeled vessels and Aβ confirmed that the amyloid deposition was not within the endothelial cells ([Figure 6(e)](#fig6-1759091417719201){ref-type="fig"}). We therefore determined that CAA-like deposition of Aβ was outside of the brain endothelial cells within the basement membranes surrounding vessels of various diameters and is potentially higher in LPS-treated E4FAD+ mice. Figure 6.CAA-like deposition is higher in E4FAD+ mice. (a) Mosaic images of 12 µm sections costained for laminin (green) and Aβ (blue) stitched together from individual 20× images. (b) Quantification of Aβ-laminin costaining. (c to e) 3D reconstruction from 63× confocal image of a cortical (c) larger vessels or (d, e) capillary stained for Aβ (blue) and (c, d) laminin (green) or (e) CD31 (red) indicating that CAA-like deposition is outside of the blood vessel within the basement membrane. (b) \**p* \< .05 by two-Way ANOVA followed by Bonferroni post hoc comparisons comparing all groups.

Plasma Cytokine Levels Are Modulated by APOE Genotype and LPS Treatment {#sec21-1759091417719201}
-----------------------------------------------------------------------

To dissect whether LPS induced a differential response in peripheral inflammation for the different groups, plasma levels of 23 cytokines/chemokines were assessed by multiplex analysis. Our focus was on cytokines/chemokines whose levels remained changed over a longer time period after each LPS treatment, rather than acute differences. Therefore, we waited 24 hr after the last LPS injection to assess cytokine/chemokine levels. In general, cytokine levels were varied within each group, likely due to the time point selected for analysis, as typically cytokines are assessed within an hour of LPS injection (i.e., high levels). However, hierarchical cluster analysis of the complete data set (i.e., significant and nonsignificant differences) revealed that LPS induced a number of potentially interesting changes ([Figure 7(a)](#fig7-1759091417719201){ref-type="fig"}). Overall, there was a cluster (C1) of chemokines (macrophage inflammatory protein \[MIP\]-1) and pro-inflammatory cytokines (interleukin \[IL\]-6, IL-5, and tumor necrosis factor \[TNF\]-α) whose levels were similar for all PBS-treated groups, but were increased by LPS. A second cluster (C2) increased in levels with LPS in E4FAD+ and E4FAD− mice and included chemokines (regulator on activation, normal T cell expressed and secreted (RANTES), granulocyte-colony stimulating factor (G-CSF)) and cytokines whose function can be pro- or anti-inflammatory depending on context (IL-1α, IL-10). In addition, cytokines/chemokines in a third larger cluster (C3) were higher in E3FAD+ or E3FAD− compared to E4FAD+ or E4FAD− in the PBS group and remained high, or were lower in the LPS-treated mice. C3 included both pro- and anti-inflammatory cytokines. Figure 7.LPS induced various changes in peripheral cytokine levels. (a) Heatmap of peripheral cytokines indicating three hierarchical clusters. In C1, cytokine levels were generally increased by LPS. In C2, cytokine levels were generally lower following LPS treatment. C3 contained cytokines/chemokines that were higher in E3FAD+ or E3FAD− compared to E4FAD+ or E4FAD− in the PBS group and remained high, or were lower in the LPS-treated mice. (b) Cytokines that were similar in the VC group, but levels increased with *APOE4* following LPS treatment. (c) Cytokines whose levels were higher with *APOE3* compared to *APOE4* in PBS or LPS treatment groups. In (b), \**p* \< .05 by three-way ANOVA followed by Bonferroni post hoc analysis comparing PBS to LPS treatments for the grouped averages of *APOE4* (i.e., E4FAD+ and E4FAD−) or *APOE3* (i.e., E3FAD− and E3FAD+). In (c), \**p* \< .05 by three-way ANOVA followed by Bonferroni post hoc analysis comparing within PBS or LPS groups the values for mice that express *APOE3* (E3FAD− and E3FAD+) to mice that express *APOE4* (E4FAD− and E4FAD+).

We further dissected the data based on significantly different changes, which reduced the overall number of cytokines. Although there were changes in some cytokines/chemokines regardless of *APOE* or FAD status (e.g., IL-6, MIP-1α in C1), we have focused on differences between *APOE3* and *APOE4*, due to the cognitive and cerebrovascular dysfunction in E4FAD+ mice treated with LPS. In C2, there was significance by *F* test for IL-10 (*F*(7, 59) = 2.5, \**p* \< .05) and RANTES (*F*(7, 64) = 6.8, *p* \< .05). Visually, the differences appeared driven by increased plasma levels of IL-10 and RANTES in mice that express *APOE4* (i.e., E4FAD+ and E4FAD−) treated with LPS compared to PBS ([Figure 7(b)](#fig7-1759091417719201){ref-type="fig"}). These changes were significant using Bonferroni post hoc analysis that compared PBS to LPS treatments for the grouped averages of *APOE4* (i.e., E4FAD+ and E4FAD−) or *APOE3* (i.e., E3FAD− and E3FAD+). In addition, although not significant by *F* test, a post hoc analysis revealed the same effect for G-CSF (i.e., LPS increased plasma levels in mice that express *APOE4* \[E4FAD− and E4FAD+ averaged\] but not *APOE3*). For cytokines in C3, there was also a genotype effect, but in the PBS groups. Our analysis for the cytokines in C3 was based on the representation of the data that indicated a genotype effect in the PBS group ([Figure 7(c)](#fig7-1759091417719201){ref-type="fig"}). In the PBS group, IL-17 and IL-12(p70) levels were higher when the average value for mice that express *APOE3* (E3FAD− and E3FAD+) was compared to the average of mice that express *APOE4* (E4FAD− and E4FAD+) (with Bonferroni correction). In the LPS group, there were no *APOE* genotype differences (for IL-17 or IL-12(p70)). For CXCL1 (KC), there was a genotype effect in the LPS group but not in the PBS group using a similar comparison, which suggests higher KC levels with *APOE3*. Therefore, in general for group C3, the cytokine/chemokine levels are lower with *APOE4* in the PBS group. As there were no specific differences in E4FAD+ mice treated with LPS compared to E4FAD− mice, the observed cytokine changes may contribute to, but not drive, the cerebrovascular impairments observed in E4FAD+ mice treated with LPS.

Discussion {#sec22-1759091417719201}
==========

Increasing evidence supports that cerebrovascular dysfunction is a key component of AD; however, the role of known AD hits in cerebrovascular dysfunction is unclear. Here we demonstrate that peripheral inflammation, *APOE4*, and Aβ interact to induce cognitive and cerebrovascular dysfunction. Our ongoing studies are focused on validating and further dissecting the contrasts identified in this study.

The first important finding is that repeated peripheral challenge with LPS induces cognitive impairment in male E4FAD+ mice. Our data are partially consistent with previous studies where acute or extended, daily (3--7 days) LPS treatment induced cognitive deficits in mice and rats ([@bibr70-1759091417719201]; [@bibr77-1759091417719201]; [@bibr79-1759091417719201]; [@bibr87-1759091417719201]) and exacerbated cognitive deficits in models of aging ([@bibr15-1759091417719201]) and neurodegeneration ([@bibr19-1759091417719201]; [@bibr43-1759091417719201]). Further, human data suggest peripheral inflammation is linked to AD risk ([@bibr63-1759091417719201]) and cognitive function in aging ([@bibr58-1759091417719201]). However, our paradigm enabled us to delineate that repeated peripheral challenge with LPS, *APOE4*, and Aβ interact to induce cognitive deficits. For acute peripheral inflammation, there is evidence of worse functional (noncognitive) outcomes with *APOE4.* Acute LPS-induced hypothermia is greater with *APOE4* compared to *APOE3* in *APOE*-targeted replacement mice (that do not overproduce Aβ), and LPS-induced hyperthermia is greater with *APOE4* compared to *APOE3* in humans ([@bibr30-1759091417719201]). Thus, there is a growing body of evidence supporting that *APOE4* and peripheral inflammation interact to induce detrimental functional responses. Future studies aimed at fully dissecting the temporal sequence of cognitive deficits in EFAD+ and EFAD− mice may reveal whether the peripheral inflammation-induced cognitive decline is specific for, or accelerated by, *APOE4* and Aβ.

As the interface between the blood and the brain, the cerebrovasculature is particularly susceptible to the detrimental effects of *APOE4*, Aβ, and peripheral inflammation. Thus, our second important finding is that peripheral inflammation induced cerebrovascular dysfunction in E4FAD+ mice. These data are consistent with *in vitro*, *in vivo*, and human data that peripheral inflammation ([@bibr12-1759091417719201]; [@bibr61-1759091417719201]), *APOE4*, and Aβ are individually associate with cerebrovascular dysfunction. Further, *APOE4* synergistically interacts with vascular (including cardiovascular) risk factors, which induce cerebrovascular dysfunction, to increase AD risk (reviewed in [@bibr84-1759091417719201]). The specific changes with peripheral inflammation in E4FAD+ mice were higher cerebrovascular leakiness and lower vessel coverage. The lower vessel coverage in the subiculum and deep layer cortex of E4FAD+ mice treated with LPS may be related to the accumulation of Aβ in those brain regions in EFAD+ mice. Indeed, the accumulation of Aβ in the deep layer cortex and subiculum of E4FAD+ mice likely induces a number of pathways (see below) that predispose the brain endothelial cells to damage in response to peripheral inflammation. Alternatively/in addition, the brain region-specific increased susceptibility of the cerebrovasculature to damage in E4FAD+ mice in response to LPS may be related to: (a) vessels in the deep layer cortex and subiculum being more sensitive to damage due to the greater distance from the larger blood vessels; (b) the nature of the vessels in those regions (e.g., capillary vessels may be in higher density in those brain regions); and (c) there is a differential gene expression profile in brain endothelial cells by brain region. Our ongoing studies are focused on developing the complex techniques required to assess this issue.

Although data from human patients support that *APOE4* and AD are associated with higher cerebrovascular permeability, data on vessel coverage are unclear. Lower vessel coverage/degenerated microvasculature is observed in AD patients ([@bibr10-1759091417719201]; [@bibr36-1759091417719201]; [@bibr8-1759091417719201]; [@bibr46-1759091417719201]; [@bibr64-1759091417719201]) and in FAD-mice ([@bibr89-1759091417719201]; [@bibr62-1759091417719201]; [@bibr51-1759091417719201]; [@bibr32-1759091417719201]). Contrastingly, higher vessel coverage (potentially angiogenesis) is also observed by other studies in AD patients and *in vivo* ([@bibr7-1759091417719201]; [@bibr6-1759091417719201]; [@bibr11-1759091417719201]). Therefore, there is currently a debate on the significance of changes in cerebrovascular length in AD. One proposal is that AD pathways induce hypersprouting and tight junction disruption, which increase cerebrovascular permeability ([@bibr7-1759091417719201]; [@bibr6-1759091417719201]; [@bibr11-1759091417719201]). A counter argument is that lower cerebrovascular coverage contributes to AD progression by disrupting the complex transport and metabolic systems of the cerebrovasculature ([@bibr67-1759091417719201]; [@bibr46-1759091417719201]; [@bibr24-1759091417719201]; [@bibr42-1759091417719201]). Our data may be more consistent with pathological angiogenesis ([@bibr2-1759091417719201]): AD hits disrupt brain endothelial cell signaling cascades that are considered angiogenic; however, rather than promoting angiogenesis, brain endothelial cells become disrupted resulting in vessel degeneration. The temporal sequence of this disruption leads to progressive brain endothelial cell degeneration and increased leakiness of the cerebrovasculature. Our ongoing studies are focused on defining the temporal sequence of brain endothelial cell dysfunction induced by AD hits.

A potential consequence of cerebrovascular damage is higher Aβ levels. Indeed, E4FAD+ mice appeared to have higher total levels of Aβ42 when challenged repeatedly with systemic LPS. Higher permeability of the cerebrovasculature may lead to the extravasation of peripheral factors, including LPS, into the brain. LPS has been demonstrated to alter amyloid precursor protein expression ([@bibr9-1759091417719201]; [@bibr37-1759091417719201]), increase Aβ production ([@bibr50-1759091417719201]; [@bibr44-1759091417719201]), and decrease Aβ clearance ([@bibr41-1759091417719201]; [@bibr27-1759091417719201]). Higher Aβ levels may deposit in the vasculature as CAA. Indeed, LPS-treated E4FAD+ mice had higher Aβ accumulation in the basement membrane of both larger vessels and capillaries. In humans, CAA is observed in approximately 90% of AD brains (reviewed in [@bibr92-1759091417719201]) and is higher with *APOE4* ([@bibr78-1759091417719201]), consistent with our *in vivo* findings. Here, our low sample number and volume did not permit assessments of amyloid precursor protein levels/processing or a detailed analysis of CAA localization. However, our ongoing studies are focused on the role of LPS in Aβ production, clearance, and CAA-like deposition.

An important question raised by this current study is what temporal changes in cytokines/chemokines were induced by repeated (weekly) low-dose LPS treatment? Potential outcomes include: (a) LPS induced weekly transient (likely over 24 hr) changes in plasma cytokines that were similar after every injection and were sufficient to induce cerebrovascular dysfunction; (b) Initial LPS treatments preconditioned the mice to a greater transient cytokine/chemokine response with subsequent injections; (c) There was a cumulative (i.e., chronic and sustained) detrimental cytokine/chemokine profile in the plasma during the course of the LPS treatment, in addition to acute transient changes; (d) A tolerance to LPS developed with multiple injections; (e) Cytokine/chemokine levels in the brain were altered which mirrored or were distinct from the plasma; and (f) *APOE* modulated one or all of the above responses. A limitation of this current study is that cytokine levels were not assessed at different time points in the plasma during treatment and, due to sample limitation, brain cytokine levels were not measured; both concerns are the focus of our ongoing studies. For example, for neuroinflammation, interesting questions include whether (a) direct or indirect (via cytokines/chemokines) LPS-induced activation of brain endothelial cells transmits cytokine into the brain (via transcytosis or cytokine production by brain endothelial cells); (b) cerebrovascular leakiness leads to LPS extravasation into the brain, glial activation and a modulated neuroinflammatory cytokine/chemokine profile that contributes to cognitive impairment; and (c.) the temporal relationship between neuroinflammation, cerebrovascular dysfunction, and cognitive impairment. Here, plasma cytokines/chemokines were measured 24 hr after the last injection. Twenty-four hours was selected as a time point to mimic slightly longer term cytokine/chemokine changes with LPS after repeated past stimulation intervals, rather than acute changes immediately after treatment. Our justification was that sustained cytokine changes may contribute to cerebrovascular dysfunction over the 2-month period of LPS treatment. However, due to the time point selected, there was a mixed and varied response within groups.

We have focused the discussion on cytokines that significantly differed between *APOE3* and *APOE4* and therefore may contribute to the cerebrovascular deficits described earlier. We are careful not to over-interpret these results as immediate changes in cytokine levels may have eluded detection at 24 hr, and all the cytokines measured exert multiple cellular functional responses (e.g., T-cell response and macrophage activation). Two *APOE*-modulated cytokine clusters were identified. The first (C2; G-CSF, IL-10, and RANTES) included cytokines that were higher in LPS-treated mice that express *APOE4* (E4FAD+ and E4FAD− mice) compared to the PBS group. RANTES promotes angiogenesis ([@bibr93-1759091417719201]; [@bibr59-1759091417719201]; [@bibr82-1759091417719201]; [@bibr53-1759091417719201]), while G-CSF and IL-10 have been demonstrated to both protect/maintain and disrupt the vasculature ([@bibr48-1759091417719201]; [@bibr20-1759091417719201]; [@bibr88-1759091417719201]; [@bibr45-1759091417719201]; [@bibr1-1759091417719201]; [@bibr14-1759091417719201]; [@bibr53-1759091417719201], [@bibr55-1759091417719201]; [@bibr95-1759091417719201]). Therefore, it is possible that the C2 cytokines initiated angiogenic signaling in E4FAD+ and E4FAD− mice, without maturing into stable vessels, or induced direct brain endothelial cell disruption in a chronic setting. In the second cluster (C3; IL-12(p70), IL-17, and KC), cytokine levels were higher with *APOE3* compared to *APOE4* in the PBS group, except for KC, which was higher in the *APOE3* LPS treatment groups. IL-17 and KC have both been reported to have pro-angiogenic effects ([@bibr69-1759091417719201]; [@bibr54-1759091417719201]; [@bibr65-1759091417719201]; [@bibr94-1759091417719201]). In contrast, IL-12 results in disruption of angiogenesis ([@bibr81-1759091417719201]; [@bibr98-1759091417719201]). Although we did not track peripheral cytokine differences longitudinally, it is possible that higher levels of IL-17 and KC in E3FAD+ and E3FAD− mice prior to an inflammatory insult confer a protective effect on the cerebrovasculature, which is absent in E4FAD+ and E4FAD− mice. It is important to note that no cytokine differences were observed between E4FAD+ and E4FAD− mice.

Mechanistically, *APOE4*, Aβ and peripheral inflammation modulate multiple processes that may interact to induce cognitive decline. The proximal mechanism(s) of how each AD hit individually impacts disease progression is complex. As an example, apoE4 may induce detrimental changes in apoE-containing lipoprotein structure, lipidation, stability, toxic apoE fragment production, apoE levels, apoE receptor recycling, and receptor activity in a number of cell types (reviewed in [@bibr83-1759091417719201]). As a consequence of one or more of these proximal events, interlinked processes in the periphery (cholesterol metabolism and inflammation) and brain (lipid homeostasis, neuronal function, glucose metabolism, neurogenesis, tau phosphorylation, neuroinflammation, Aβ levels) are modified. Thus, apoE4 may directly induce brain endothelial cell dysfunction via signaling ([@bibr66-1759091417719201]), or indirectly through peripheral and central processes ([@bibr4-1759091417719201]; [@bibr13-1759091417719201]; [@bibr34-1759091417719201]). The interaction among the AD hits is equally as complex for two AD hits, which is amplified by the addition of a third. ApoE4 modulates Aβ levels, Aβ-dependent signaling, and the response to peripheral inflammation. Our ongoing studies are focused on delineating the potential CNS- and peripherally-relevant changes that may underlie these effects.

Through collective analysis of our data, we hypothesize that LPS-induced cerebrovascular and cognitive damage in E4FAD+ mice in response to repeated LPS challenge is mediated by complex processes within the central nervous system and the plasma in the paradigm utilized (i.e., LPS treatment from 4 to 6 months of age). In the central nervous system, the combination of *APOE4*- and Aβ-modulated processes (described earlier) converge, to predispose brain endothelial cells of the cerebrovasculature to damage. In the periphery, *APOE4* modulates the inflammatory response to LPS, resulting in a detrimental peripheral cytokine/chemokine profile that is characterized by higher detrimental and lower protective factors for brain endothelial cell function. The collective result is brain endothelial cell disruption, cerebrovascular leakiness, and cognitive impairment only in E4FAD+ mice. An important future direction is to determine whether E3FAD+ mice or E4FAD− mice are the next group to exhibit cerebrovasculature and cognitive impairments after longer LPS treatment.

In summary, peripheral inflammation interacts with *APOE4* and Aβ to induce and accelerate cerebrovascular and cognitive deficits. Thus, cerebrovascular dysfunction is a key mechanistic process linking AD hits to pathology.

Summary {#sec23-1759091417719201}
=======

Peripheral inflammation interacts with *APOE4* and Aβ to induce cerebrovascular and cognitive deficits.
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For all representative mosaic images the following was conducted using the Zeiss Axio Imager M1 software and a motorized stage at 20× magnification: the boundaries of each individual brain section were set that included the hippocampus and cortex using the mosaic function, sequential images were obtained that encompassed the entire area of the tissue boundary (between ∼50 and 150 images per section), and all the individual images were then stitched together to produce a single composite image.

As apoE levels were assessed in EFAD+ and EFAD− mice, a three-way ANOVA *F* test was conducted.
